Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
AIDS Malignancy Consortium
Taiho Oncology, Inc.
Adela, Inc
Implenomics
Memorial Sloan Kettering Cancer Center
OncoNano Medicine, Inc.
Mayo Clinic
University of Southern California
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
Arcus Biosciences, Inc.
Washington University School of Medicine
UNC Lineberger Comprehensive Cancer Center
University Medical Center Groningen
Tempus AI
Seagen Inc.
RAPT Therapeutics, Inc.
Taproot Health
Sanguine Biosciences
Corvus Pharmaceuticals, Inc.
Fate Therapeutics
Fate Therapeutics
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
University Hospital Southampton NHS Foundation Trust
Incyte Corporation
Jonsson Comprehensive Cancer Center
MultiVir, Inc.
Barts & The London NHS Trust
Tel-Aviv Sourasky Medical Center
National Institutes of Health Clinical Center (CC)
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
University of Washington
University of Alabama at Birmingham
Rutgers, The State University of New Jersey
Memorial Sloan Kettering Cancer Center
INSYS Therapeutics Inc
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
The University of Hong Kong
Murdoch Childrens Research Institute
Netherlands Open University